| NCT01361217 | Drug-Drug Interaction|Healthy Volunteers | Drug: Fluoxetine | University of Washington|National Institute of General Medical Sciences (NIGMS) | | 2011-09-01 | 2012-06-18 |
| NCT00986310 | Uncontrolled Partial Epilepsy|Ictal Hypoventilation | Drug: Fluoxetine|Drug: Placebo | University of California, Davis|Citizens United for Research in Epilepsy | | 2009-08-01 | 2012-11-02 |
| NCT00778024 | Healthy | Drug: fluoxetine HCL 40 mg capsules | Ranbaxy Laboratories Limited|Ranbaxy Inc. | | 2003-08-01 | 2009-12-11 |
| NCT01166087 | Healthy | Drug: Fluoxetine Hydrochloride | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-02-01 | 2010-07-20 |
| NCT01166100 | Healthy | Drug: Fluoxetine Hydrochloride | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-02-01 | 2010-07-20 |
| NCT00115804 | Juvenile Primary Fibromyalgia Syndrome (JPFS)|Fibromyalgia | Drug: Fluoxetine | University of Cincinnati | Phase 3 | 2005-06-01 | 2017-02-06 |
| NCT02569970 | Epilepsy|Ictal/Post-ictal Hypoxemia | Drug: fluoxetine 20 mg|Drug: placebo 20 mg | Hospices Civils de Lyon | Phase 3 | 2010-11-01 | 2016-10-04 |
| NCT01146548 | Multiple System Atrophy | Drug: FLUOXETINE | University Hospital, Toulouse|Clinical Research Center, Toulouse | Phase 2 | 2008-05-01 | 2015-03-25 |
| NCT00149643 | Depressive Disorder, Major|Cannabis Abuse | Drug: Fluoxetine|Other: Placebo | University of Pittsburgh|National Institute on Drug Abuse (NIDA) | Phase 2 | 2004-09-01 | 2013-06-17 |
| NCT00633685 | Posttraumatic Stress Disorder, Combat-related | Drug: Fluoxetine|Drug: Placebo | TEMPVA Research Group, Inc.|C.R.Darnall Army Medical Center|Central Texas Veterans Health Care System|VA Boston Healthcare System | Phase 4 | 2010-03-01 | 2010-05-24 |
| NCT00573547 | Depression | Drug: Fluoxetine | Creighton University | Phase 4 | 2007-02-01 | 2011-08-15 |
| NCT00245635 | Body Dysmorphic Disorder | Drug: Fluoxetine|Drug: Placebo | Montefiore Medical Center|Food and Drug Administration (FDA) | Phase 4 | 2004-11-01 | 2015-07-06 |
| NCT01615055 | Cognitive Dysfunction | Drug: Fluoxetine|Drug: Placebo | University of California, Los Angeles|Beckman Research Institute | | 2018-06-01 | 2016-02-04 |
| NCT00183339 | Autistic Disorder | Drug: Fluoxetine|Drug: Placebo | University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH) | Phase 2 | 2005-07-01 | 2014-02-07 |
| NCT01247272 | Healthy | Drug: Fluoxetine Hydrochloride|Drug: PROZAC WEEKLY庐 | Teva Pharmaceuticals USA | Phase 1 | 2001-05-01 | 2011-01-24 |
| NCT01247285 | Healthy | Drug: Fluoxetine Hydrochloride|Drug: PROZAC WEEKLY庐 | Teva Pharmaceuticals USA | Phase 1 | 2001-05-01 | 2011-01-24 |
| NCT01075529 | Major Depressive Disorder | Drug: fluoxetine | Kaohsiung Kai-Suan Psychiatric Hospital | Phase 4 | 2007-03-01 | 2010-02-24 |
| NCT02063425 | Cerebral Infarction | Drug: Fluoxetine|Drug: Placebo of fluoxetine | Centre Hospitalier St Anne | | 2014-02-01 | 2016-02-11 |
| NCT02737930 | Acute Stroke|Visual Field Loss | Drug: Fluoxetine|Drug: Placebo | Bogachan Sahin|University of Rochester | Phase 2 | 2016-05-01 | 2016-10-25 |
| NCT00758966 | Obsessive-Compulsive Disorder | Drug: Fluoxetine 60 mg|Drug: Naltrexone 32 mg and fluoxetine 60 mg|Drug: Naltrexone SR 32 mg | Orexigen Therapeutics, Inc | Phase 2 | 2008-09-01 | 2012-11-27 |
